Back to mobile site
Get it on Google Play

Compass Pathways receives FDA rolling review for psychedelic depression drug

April 24, 2026 10:37 AM EDT Send to a Friend
Compass Pathways plc (NASDAQ: CMPS) announced the U.S. Food and Drug Administration granted the company a rolling New Drug Application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login